Phase II study of liposomal doxorubicin and gemcitabine in the salvage treatment of ovarian cancer

In total, 70 patients were enrolled into this phase II study, to evaluate the activity of the pegylated liposomal doxorubicin (PLD) and gemcitabine (GEM) combination in recurrent ovarian cancer patients. PLD, 30 mg m(−2), was administered on day 1 by 60′ i.v. infusion, followed by GEM, 1000 mg m(−2)...

Cijeli opis

Spremljeno u:
Bibliografski detalji
Glavni autori: D'Agostino, G, Ferrandina, G, Ludovisi, M, Testa, A, Lorusso, D, Gbaguidi, N, Breda, E, Mancuso, S, Scambia, G
Format: Artigo
Jezik:Inglês
Izdano: Nature Publishing Group 2003
Teme:
Clinical
Online pristup:https://ncbi.nlm.nih.gov/pmc/articles/PMC2394291/
https://ncbi.nlm.nih.gov/pubmed/14520442
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1038/sj.bjc.6601284
Oznake: Dodaj oznaku
Bez oznaka, Budi prvi tko označuje ovaj zapis!

Similar Items